INTRODUCTION

Pathogenic bacteria produce a wide range of constituents, which determine their virulence and host responses following infection. In the case of Mycobacterium tuberculosis (MtB), antigenic and immunomodulatory constituents may be considered as virulence factors, because they can act as “decoys,” triggering excessive immune responses which can lead to pathology of the lungs in active tuberculosis (TB), instead of host protection (1). Hence, immunological research has been essential for the study of pathogenesis as well as for the development of prophylactic vaccination and for the detection of latent infection. Detailed analysis of the specificity and of the phenotype of immune responses is mandatory in the desire to discover biomarkers for protective immunity, for predicting the risk of reactivation from latent infection and for developing immunotherapies, adjunct to chemotherapy.

Dissection of the antigenic structure of MtB to its epitope constituents has been driven by the newly developed technologies, starting with hybridoma-produced monoclonal antibodies (2, 3), followed by recombinant DNA expression libraries (4), T-cell cloning and hybridomas (5), and DNA sequencing. More recently, new epitopes predicted within the whole MtB genome on the basis of algorithms (“silico mapping”) (6) have a useful rate of empirical confirmation (7). The location of discontinuous and conformational epitopes recognized by antibodies can be predicted by integrated analysis of the dynamical and energetic properties of proteins (8). Mapping of T-cell epitopes within the known protein sequence used synthetic peptides with overlapping sequence (“pepscan”) and single-residue substitutions identified epitope cores, flanks, and key residues involved in binding to major histocompatibility complex (MHC) or T cell receptor (TcR) molecules.

Characterization of the membrane markers and cytokine profiles of responding T cells identified the existence of T-cell subsets and their regulatory networks. Emphasis on the T-cell phenotype and recently on the transcriptomic signature of T cells is currently expanding (9), but without full attention to antigen and epitope specificity. However, restoring the balance of knowledge between the functional phenotype and recognition specificities of T cells seems compelling.

The extensive knowledge on the mapping of antigenic epitopes has been cataloged and made accessible by the NIH IEDB database http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228276/; http://www.iedb.org/; http://help.iedb.org/entries/19150-user-documentation-iedb-version-2.

This inventory contains more than 1000 epitopes, mostly derived from only about 30 of the most immunogenic antigens,
representing a very small fraction from the about 4000 known open reading frame proteins of the Mtb genome (10). Recently combined analysis of epitope predictions, high throughput ELISPOT, and T-cell libraries from latently Mtb-infected subjects, categorized the epitopes into prominent “antigenic islands” (11). The wider significance of epitope specificity of immune responses of Mtb-infected hosts has been reviewed recently (12).

This chapter points out the role of individual epitope specificities and aims to integrate this knowledge with different functions, relevant for the host–parasite relationship. Potentials for future research are targeted at improving the control of TB, particularly for vaccination, immunotherapy, detection of latent infection, and early diagnosis of infectious forms of active disease.

**MHC-PERMISSIVE EPITOPES**

Immunodominant epitopes were originally thought to be recognized in the context of only one or a few MHC class II alleles, though a number of genetically permissive epitopes were found in microbial pathogens. Initial mapping of CD4 T-cell stimulatory epitopes showed two hsp65 peptides recognized by several H-2-disparate mouse strains, one of them presented by both I-A and I-E molecules (13). Subsequent analysis of two glyco-lipoproteins and the α-crystallin (Acr) antigen identified the same few epitopes as immunodominant in a number of inbred strains of mice, carrying different H-2A alleles (14–16). H2I-A promiscuous recognition of p350–369 was demonstrated using CD4 T-cell hybridomas, though with allele-specific binding of IA polymorphic critical residues (17). Moreover, pepscan analysis revealed separate patterns of recognition by T hybridomas of the same H-2 haplotype, whereby every core residue was critical for at least one hybridoma, with only one substitution (74 Val → Ala) common to all hybridomas (18). While core residues were critical for both MHC and TcR binding, T-cell recognition was influenced also by the substitution of flanking residues (19).

The apparently abundant occurrence of MHC-permissive epitopes in tubercle bacilli may be an evolutionary consequence of selection of mutants carrying protective MHC-permissive epitopes. These organisms would have been advantageous to the pathogen, by being conducive to the longer survival of individuals, who were capable of aerosol transmission of the infection. This evolutionary concept is supported by the finding that the majority of clones used the HLA-DR-binding and TcR-binding cores and contact residues within the DR17 restricted p3–13 epitope from the hsp65 antigen. Using this approach, TcR V gene families of human CD4 T-cell clones were analyzed in respect of the most immunodominant, HLA-DR promiscuous 91–110 epitope of Acr (25). The HLA-DR-binding and TcR-binding cores and contact residues were identified within 9-mer or 13-mer cores, which differed between the DR haplotypes. Notably, preferential TcR usage was demonstrated by the finding that the majority of clones used the BV2 TcR and contained a common R-L/V-G-Y-W-E/D sequence motif in the CDR3 region (36). These data may be useful to design peptides with altered HLA anchor residues or TcR interaction sites to increase their immunogenicity.

The “in silico” algorithms (ProPred1) predicted a number of HLA class I-permissive epitopes in histone or proteins of undefined function from Mtb (37). ProPred prediction of Mycobacterium leprae epitopes identified a number of both class I and II, HLA-permissive T-cell reactivity, in leprosy endemic populations in Brazil, Ethiopia, and Nepal (38). Comparing algorithms for HLA-binding promiscuity between ecologically diverse human microbial pathogens, found the promiscuity of Mtb epitopes to be of a similar degree as in HIV, S. pyogenes, or even higher for B. anthracis and C. tetani (39). However, these epitope predictions need empirical confirmation and should take into account that HLA binding affinities may not always associate with the magnitude of T-cell responses.

**CROSS-REACTIVITY OF MYCOBACTERIAL EPITOPES**

The antigens of Mtb are related to a number of proteins from non-tuberculous mycobacterial pathogens or commensal
non-pathogenic mycobacterial species and more rarely with human proteins. These relationships are of interest, because environmental priming can influence resistance to Mtb, it can interfere or enhance the protective immune response to vaccination and may exclude from vaccine development, any molecules that can lead to autoimmunity. The latter category includes the chaperonins hsp65 and hsp71 with highly conserved sequences between prokaryotic and eukaryotic species and consequently extensive cross-reactivity between mycobacteria and humans (40). An hsp65 epitope at sequence 285–295, detected by mAb ML30 is strongly expressed on the surface of human cells with abundant mitochondria (40). Elevated expression was observed on monocyte-derived cells in different inflammatory diseases, including rheumatoid arthritis (41), atherosclerosis (42–44), and multiple sclerosis (45).

Analysis of antigen homologs from different species of mycobacteria showed that cross-recognition by T cells requires sharing fewer amino acids than cross-reaction by antibodies. Thus, polyclonal and monoclonal antibodies to ESAT-6 from Mtb and M. leprae, which share only 36% amino acids, are all strictly species-specific (46). In contrast, recombinant ESAT-6 from both species are similarly recognized by T cells from individuals, who were exposed to either tuberculous or leprosy infection (46). Cross-reactivity at the level of T-cell, but not B-cell recognition can lead to the recall of antibody production with specificity for the initial antigen (term: “original antigenic sin”) (47). This interpretation was given to the finding of elevated antibody levels against Mtb-specific epitopes in lepromatous leprosy patients from TB endemic areas (48). However, M. leprae-specific antibodies in patients with active TB were not raised, since these patients were probably not exposed to M. leprae infection.

Cross-reactivity without sequence homology, i.e., mimicry, has been observed with a broad range of molecules of different structure, such as lactoferrin, transferrin, and proteoglycan. Another example of mimicry is the cross-recognition by CD4 T cells of an octamer epitope on two unrelated mycobacterial proteins, which is immunodominant for the 19-kDa protein of Mtb and cryptic for the 28-kDa protein of M. leprae (49, 50). Assumptions that epitope-based mimicry between proteins could lead to unsuspected cross-sensitization, maintain T-cell memory, or lead to autoimmunity, need further study.

Despite wide sequence homologies, heat shock proteins contain also species-specific epitopes. Increased Mtb-specific antibody levels were reported for hsp65, hsp71 (51, 52) in patients with active TB, including patients with smear-negative disease, which remains a diagnostic obstacle. Elevated serum antibodies to mycobacterial, but not to human hsp65 in Crohn’s disease, implied a pathogenic role of mycobacteria, whereas antibodies in ulcerative colitis bound to human hsp65 (53). Further support for the mycobacterial pathogenesis of Crohn’s disease came from the finding of elevated antibody levels against three different antigens derived from Mycobacterium paratuberculosis (54).

Immunodominant species-specific T- and B-cell epitopes can be found in a mycobacterial 10-kDa GroEL heat shock protein despite its highly conserved amino acid sequence. Despite a 90% sequence identity with Mtb, studies in mice identified two M. leprae-specific closely overlapping CD4 T-cell epitope cores (24–34 and 28–34), restricted by H-2Ad and H-2Ed, respectively and overlapping with an M. leprae-specific mouse mAb (ML6 and 10) epitope at residues 25–31 (55). The lack of antibody response to this epitope in lepromatous leprosy patients was suggested to be due to the T-cell epitope overlap.

The CD4 T-cell epitope repertoire of GroES was investigated also in TB and leprosy patients. The N-terminal (1–16) peptide (residues 1–16) was specifically stimulatory in the majority of active TB patients (56), while none of the other peptides was discriminatory. On the other hand, peptide 25–40 (29–37 core) of M. leprae, but not of Mtb sequence was specifically stimulatory in tuberculoid leprosy patients; this peptide bound to a number of HLA-DR molecules, of which HLA-DRB5*0101 had the strongest affinity (24). Four other leprosy-specific epitopes were identified on the 35-kDa protein of M. leprae, which has a homologous constituent in M. avium, but not in Mtb (57). Analysis of epitope specificities explained the phenomenon of split leprosin/tuberculin anergy of skin hypersensitivity in a proportion of leprosy patients. Thus, blood T-cell proliferative responses were found to be diminished to cross-reactive antigens, but elevated toward the predominantly Mtb-expressed PstS1 antigen and the Acr epitope 71–91 (58).

A special case of cross-reactivity is the induction of epitope-specific immune responses by anti-idiotype (Id) antibodies, acting

---

**Table 1** Mtb antigens with identified HLA-DR-permissive CD4+ T-cell stimulatory epitopes.

| Protein group     | Antigen name       | Gene accession no. | kDa | Epitope sequence | Reference               |
|-------------------|--------------------|--------------------|-----|------------------|-------------------------|
| Glyco-lipoprotein | PstS1              | Rv0934             | 38  | 1–20, 350–369    | Jurevic et al. (22)     |
| Chaperonin stress proteins | α-Crystallin, Acr | Rv2031             | 16  | 91–110           | Caccamo et al. (25)     |
|                   | GroEL2, hsp65      | Rv0440             | 65  | 61–75, 141–155   | Mustafa et al. (23)     |
|                   | GroES              | Rv3418c            | 10  | 25–40            | Chua-Intra et al. (24)   |
| RD-1, ESX family  | ESAT-6, EsxA       | Rv3875             | 6   | 1–20             | Tully et al. (27)       |
| Secreted proteins | Ag85B mycolyl transferase | Rv1886c        | 30–32 | 91–108         | Valle et al. (28)       |
|                   | CFP-10, EsxB       | Rv3874             | 10  | 71–88            | Shams et al. (26)       |
|                   | MPB70, mpt70       | Rv2875             | 22  | 106–130, 166–190 | Al-Attiyah et al. (29)   |
| Cell surface      | PPE family         | Eight genes        | 3–316| Eight epitopes | Wang et al. (30)        |
as the epitope’s “internal image.” This was demonstrated for both mouse and human CD4 T-cell responses, using rabbit anti-Ids raised against PstS1-specific mouse mAbs (59, 60). However, the corresponding structural determinants remained undefined and the approach has been overtaken by the more exact recombinant DNA and synthetic peptide technologies. Id specificities have also been identified on anti-DNA autoantibodies stimulated probably by bacterial polyclonal B-cell activation in patients with TB and leprosy (61, 62).

**T-CELL EPITOPE ANALYSIS IN LATENT Mtb INFECTION**

*Mycobacterium tuberculosis* infection is routinely being monitored by skin delayed type hypersensitivity (DTH) reactions against tuberculin (PPD), a crude extract from *M. tuberculosis*. This test has poor specificity, due to cross-reactivity with environmental mycobacteria and vaccination by Bacillus Calmette-Guérin (BCG). The discovery of Mtb-specific, immunodominant, HLA-permissive epitopes, led to the use of synthetic peptide for the *in vitro* stimulation of blood T-cell responses. The numerous candidate peptides described (not reviewed here) have all been selected from several antigens on the grounds of better specificity than PPD, but they are performing at lower sensitivity than PPD. Improvements to sensitivity by using peptide pools has however had a limited impact, because of overlapping, rather than complementary recognition by the T-cell repertoire (22). The increase in stimulation by a pool of eight different peptides over the best single peptide (p91–110 from Acr) has been merely marginal. This outcome was attributed to HLA permissiveness and to competition between peptides for a limited number of binding sites on the HLA class II molecules of the APCs. This latter explanation has been supported by the finding of a declining response trend to higher concentrations of pools, but not of single peptides.

Nevertheless, commercially available IFNγ detection kits (IGRA), e.g., QuantiFERON-TB Gold (QTF-G), T-SPOT.TB etc. have been widely used for the specific detection of latent Mtb infection. They usually contain a mixture of several epitopes, predicted by algorithms of the Mtb-specific ESAT-6 and CFP-10 RD-1 antigens (absent from BCG and environmental mycobacteria). However, the use of these kits in areas highly endemic for TB is not of great added value for diagnosis. Recent side-by-side analysis of constituent antigens indicated potentials for further improvement of the test kits (63). Peptide cocktails have also been useful for the diagnosis of bovine TB in cattle, using either skin test or blood assays (64, 65). The blood INFγ assay (BOVIGRAM) readout has been further enhanced by adsorbing the peptides onto a range of microparticulate and nanoparticulate substrates (66). Detection IFNγ-induced protein (IP-10), which is produced in 100-fold greater amounts than IFNγ, has been developed for a simplified and more robust lateral flow test than IGRA (67). Notably, satisfactory results were obtained using dried plasma spots, amenable for conventional postal transport (68).

In view of the possibility that sequence variations in epitopic regions between clinical Mtb isolates might affect the results of IFNγ assays, human clinical samples were sequenced to identify substitutions that may have an impact on immunogenicity. A number of sequence polymorphisms (SNPs) have been revealed in the epitope regions of EsxB and EsxH genes (69), with evidence for recombination events, which may truncate the corresponding protein. Even single-residue differences altered the responder frequencies to these antigens from *M. bovis* isolates (70). Hence, immune variation may influence the diagnostic performance of kits, which contain epitopes from the ESX proteins.

**T-CELL EPITOPE REPERTOIRE IN ACTIVE TB**

Commercially available IGRA assays routinely used in clinical practice do not distinguish reliably between active TB and latent infection and have limited value for predicting the risk of developing active TB (71). Therefore, it has been of interest to search, if fine analysis of epitope specificities could improve the diagnosis. Proliferation assays of blood T cells from patients with active TB recognize a smaller number of Acr epitopes than sensitized healthy subjects (Table 2) (32). Similarly, patients with leprosy recognize fewer GroEL epitopes than healthy contacts (24). These findings corroborate with the previously known skin DTH anergy to PPD in a fraction of active TB patients and with the development of lepromin anergy in multibacillary leprosy. The search for epitopes, which would distinguish patients from latent infection, yielded a promising result only for the amino-terminal peptide of GroES (1–16) (56). The selective power of this peptide is surprising, considering its overlap, except for one residue, with the *M. leprae* sequence and is in need of confirmation with more clinical samples.

A reciprocal approach to the differential diagnosis has come from the finding of selective T-cell anergy in active TB in respect of the carboxy-terminal epitope p350–369 of the PstS1 antigen, which is strongly immunogenic in latent infected subjects (31). The lack of blood T-cell response can be due to sequestration to the site of disease (e.g., pleural fluid) and the ratio of T cells between these compartments is influenced by chemotherapy (72, 73). The post-chemotherapy recovery of blood response seemed more pronounced for T cells reacting with the Acr peptides, than those responding to the PstS1 peptides, which could be explained by differences in expression between replicating and

| Subjects (no. tested) | Peptides from | Frequency (%) of responders, no. of test peptides (p) |
|----------------------|--------------|--------------------------------------------------|
| Healthy PPD+ skin test (25) | Acr | 1–3 p | 4–6 p | >6 p |
| Active TB (38) | 24 | 52 | 24 |
| Healthy family contacts (12) | GroES | 1–4 p | 5–10 p | >10 p |
| Tubercoid leprosy (19) | 33 | 56 | 42 |

*a Blood mononuclear cells of responders had at least threefold elevated 3H-thymidine uptake in cultures containing the test peptide over medium alone. Data from: b Friscia et al. (32); c Chua-Intra et al. (24).
chemotherapy-generated persister organisms. While dissecting of active from latent TB T-cell repertoire merely on the grounds of epitope specificity had failed to reach consensus (72), significant differences in their cytokine secretion are represented by elevated number of polyfunctional T cells (secreting IL-2, IFNγ, and TNFα) in active TB (74).

HIV-infected subjects have a high risk of reactivating their latent Mtb infection. Predicting this outcome better than just on the grounds of declining CD4 counts, would be of prime interest. The ratio of IFNγ ELISPOT counts in response to RD-1 peptides over CD4+ T-cell counts, greater than 0.21, showed 100% sensitivity and 80% specificity for active TB (75). However, the finding of 19% non-responder TB patients limited the diagnostic scope of this study. PPD-stimulated T cells carry higher levels of HIV DNA and depleted sooner than T cells of other specificity (76). This could explain the frequent reactivation of latent Mtb infection in HIV+ subjects. The antigen and epitope specificities involved have not been studied much beyond the crude PPD extract and the mechanism, which renders Mtb-reactive cells more permissive to HIV infection, is not understood. One possibility could be the lower stimulatory dose of the HLA-permissive epitopes for T cells with high affinity TcRs. This mechanism would imply selective recognition of certain epitopes, which would be rewarding to identify in the future. So far however, attention has been directed toward the study of the CD4 T-cell phenotype, characterized as CXCR3+ CCR4+ CCR6+ CD57− IFNg+ IL-17+ IL-2hi MIP1blow for the highly HIV-permissive PPD-reactive and CXCR3+ CCR4− CCR6− CD57+ IFNg+ IL-2low MIP1bhig for low HIV-permissive CMV and other virus-reactive T cells (76).

ASSOCIATION OF HLA-DR AND ANTIBODY EPITOPE SPECIFICITY WITH TB

Susceptibility to TB is considered to be under the influence of multiple genetic loci, including HLA alleles. HLA-DR2 was found inherited more frequently in offspring with pulmonary TB, from both diseased and healthy parents (77) and associated with sputum-positive, but not with sputum-negative active pulmonary TB (78). DR2 alleles in sputum-positive TB associated also with elevated antibody levels to two epitopes of the PstS1 lipoglycoprotein antigen (79), but not with the similarly elevated antibody levels to epitopes of three other antigens of diverse nature (Acr, 19-kDa lipoglycoprotein, and lipoarabinomannan). The intriguing aspect of this finding is that both the genetic and immunological specificities were identified.

To explain the DR2 gene control of TB susceptibility, it has been proposed (80) that T-cell recognition of DR2-restricted PstS1 epitopes may lead to a Th2 response, producing IL-4 and IL-10 cytokines, which can lead to the development of lung pathology, rather than host protection. This hypothesis is supported by the finding, that selection of epitopes presented by B cells, rather than dendritic cells, diverted T cells from protection toward pathogenicity in Leishmania infection (81). Thus, the specificity of antibody responses during active TB could guide toward antigens, containing potentially pathogenic Th2 recognized epitopes. The search for such T-cell epitopes on the PstS1 antigen so far did not yield supportive data. Epitope specificity was determined only for Th1 cell clones which were mostly HLA-DR promiscuous (82) with all immunodominant epitopes of PstS1 binding to several HLA-DR molecules (22). However, these assays may not be suitable to reveal a DR2-restricted presentation of the same epitope to Th2 T cells. Development of assays for the mapping of Th2 cell stimulatory epitopes will be important to explain the mechanism of HLA class II-mediated influences on the development of multibacillary TB.

Analysis of some of the above raised aspects had been approached in mouse experimental models. Notably, influence of H-2 genes (Db or lack of I-E expression) was observed on the late progression of intraperitoneally delivered infection and pathology in the lungs, when spleen and liver bacillary counts remained stationary (83). Though this model of selective multibacillary lung disease seems relevant, the antigen specificity of the underlying immune responses was not identified. Although antibody responses to different antigens and epitopes is under H-2A control following immunization with soluble antigens in adjuvants (84, 85), there is no clear corresponding evidence following Mtb infection. On the other hand, antibody responses to hsp65 and hsp70 antigens (86) and liver granuloma formation (87) following Mtb infection were associated with non-H-2 genes.

Further analysis of the Th2 (T-helpers for B-cell responses) epitope repertoire also needs further studies in mouse models, addressing the topographical relationship between CD4 T-cell and B-cell stimulatory epitopes (88). Though using merely proliferation assays, it appeared, that PstS1 antigen immunized mice produced CD4 T cells, but not antibodies against the p65–83 peptide, which contains a non-overlapping cryptic B and an immunodominant T epitope core, while T-cell help was “delegated” probably to distantly located linear or conformational B-cell epitopes (Table 3) (89). A functional association between topographically distinct epitopes was suggested also by the finding that a single amino acid mutation of epitope core of the 19-kDa antigen abrogated T-cell, but not the B-cell immunogenicity (90).

PEPTIDE EPITOPE-BASED VACCINATION AGAINST TB

Most research toward a better vaccine against TB has been based on boosting immunity after BCG priming. The choice of antigen for this purpose has been to some extent subjective, though usually targeting proteins which appeared as most immunogenic in Mtb-infected individuals or experimental animals. Further breakdown of the immune repertoire to individual epitope specificities showed that both immune recognition was influenced by the nature of the immunogen. Thus, CD4 T cells recognized different peptides, when mice were vaccinated with either PstS1 antigen or heat-killed Mtb or infected with H37Rv bacilli (Table 3) (89). Antibodies reacted to different epitopes following vaccination, but bound only to conformational epitopes following infection. CD8 T cells also recognized different peptides following vaccination or Mtb infection (91, 92). These results indicate that the nature of the immunogen could influence antigen processing, which may deviate T-cell help from one to another B-cell epitope. Substantial differences in protection, cytokine profile, and recognition of T-cell epitopes of Ag85A or the Ag85B–ESAT-6 fusion protein were observed after its presentation either expressed in adenovirus vector or with an adjuvant (93). Disparities were observed also in response to Ag85A and its immunogenic peptides, when inoculated intranasally or parenterally (94).
Table 3 | Differences in epitope recognition between immunized and infected C57Bl/10 mice.

| Foot pad injection | T-cell proliferation to peptides | Antibody level |
|--------------------|---------------------------------|----------------|
|                     | 44– | 65– | 123– | 350– | p1– | p20– | 220– | TB71 |
| Recombinant PstS1²a | – | ++ | ++ | – | – | +++ | ++ |
| Heat-killed H37Rv³  | – | – | + | + | +++ | – | + |
| H37Rv infection     | + | + | – | – | – | – | ++ |

Magnitude of the immune response: stimulation indices: –, <1; +, 1–10; ++, 10–20 of spleen and lymph node cells 7 days after immunization.

ELISA peptide binding or TB71 mAb competition titers: –, <10; +, 10–100; ++, 100–1000; +++ >1000 in sera harvested 12 weeks after first inoculation.

²a Antigen in incomplete Freund’s adjuvant followed by three boosters without adjuvant. Data from Vordermeier et al. (69).

DNA gun bombardment has been used for the mapping of T-cell epitopes and the effect of self-adjuvanting domains. Several CD4+ and one CD8+ T-cell epitopes were identified on the DNA-binding protein 1 (MDP1) antigen (95), while spleen CD4 T cells from HLA-DRB1*0401 transgenic mice recognized only the p191–210 epitope on the MPT51 antigen (96). A fusion DNA vaccine incorporating the HSV70 C-terminal domain (as adjuvant) and MPT51 (as target antigen) stimulated CD4, but not the CD8 T-cell response (97). Though documenting immunogenicity, these results need to be extended for protection against challenge.

Vaccine design could benefit from modifying the structure of peptides to increase their immunogenicity, while conjugation of a MHC-permissive peptide could abrogate genetic restriction for another MHC-restricted epitope. Studies in this direction showed that orientation between two epitopes within a synthetic peptide dimer can profoundly influence immunogenicity (98). Orientation of peptides played a role also for chimeric peptides constructed by recombinant DNA technology (99). Immunogenicity can be increased also by extension of an epitope core with non-native flanking residues (100) or by covalent attachment to biodegradable amphoterically branched chain polypeptides (101). Lipoylation of the MHC-promiscuous 91–110 peptide of Acr inoculated without any adjuvants was reported to enhance the immunogenicity and imparted protection against aerosol Mtb challenge in both mice and guinea pigs to an even better extent than BCG (102).

TcR-LIKE LIGANDS

Tubercle bacilli multiply and persist predominantly in macrophages, which display on their surface HLA-bound antigenic mycobacterial peptides, which are recognized by T-cell receptors (TcR). T cells can impart protection, but their excessive reactions can lead also to inflammatory pathology, characteristic of active TB. To avoid the latter outcome, suitable T-cell receptor-like constructs could be protective, without the accompanying undesirable T-cell-mediated inflammation. Immunotherapy using soluble TcR ligands could kill macrophages infected with both replicating and dormant Mtb organisms. Based on this hypothesis, TcR-based immunotherapy could be used as an adjunct to chemotherapy and be particularly useful to HIV-infected TB patients, many of whom being immunocompromised, cannot be protected by active vaccination. Therefore, TcR immunotherapy might be better than “therapeutic” active vaccination and also more efficient than passive antibody therapy, which can target probably only extracellular Mtb bacilli (112, 113). Unlike antibodies to B-cell epitopes [including those directed against overlapping T and B epitopes (114)], TcR-like ligands would be directed against epitopes, displayed in complex with MHC molecules on the surface of Mtb-infected cells.

DNA gun bombardment has been used for the mapping of T-cell epitopes and the effect of self-adjuvanting domains. Several CD4+ and one CD8+ T-cell epitopes were identified on the DNA-binding protein 1 (MDP1) antigen (95), while spleen CD4 T cells from HLA-DRB1*0401 transgenic mice recognized only the p191–210 epitope on the MPT51 antigen (96). A fusion DNA vaccine incorporating the HSV70 C-terminal domain (as adjuvant) and MPT51 (as target antigen) stimulated CD4, but not the CD8 T-cell response (97). Though documenting immunogenicity, these results need to be extended for protection against challenge.

Vaccine design could benefit from modifying the structure of peptides to increase their immunogenicity, while conjugation of a MHC-permissive peptide could abrogate genetic restriction for another MHC-restricted epitope. Studies in this direction showed that orientation between two epitopes within a synthetic peptide dimer can profoundly influence immunogenicity (98). Orientation of peptides played a role also for chimeric peptides constructed by recombinant DNA technology (99). Immunogenicity can be increased also by extension of an epitope core with non-native flanking residues (100) or by covalent attachment to biodegradable amphoterically branched chain polypeptides (101). Lipoylation of the MHC-promiscuous 91–110 peptide of Acr inoculated without any adjuvants was reported to enhance the immunogenicity and imparted protection against aerosol Mtb challenge in both mice and guinea pigs to an even better extent than BCG (102).

TcR-LIKE LIGANDS

Tubercle bacilli multiply and persist predominantly in macrophages, which display on their surface HLA-bound antigenic mycobacterial peptides, which are recognized by T-cell receptors (TcR). T cells can impart protection, but their excessive reactions can lead also to inflammatory pathology, characteristic of active TB. To avoid the latter outcome, suitable T-cell receptor-like constructs could be protective, without the accompanying undesirable T-cell-mediated inflammation. Immunotherapy using soluble TcR ligands could kill macrophages infected with both replicating and dormant Mtb organisms. Based on this hypothesis, TcR-based immunotherapy could be used as an adjunct to chemotherapy and be particularly useful to HIV-infected TB patients, many of whom being immunocompromised, cannot be protected by active vaccination. Therefore, TcR immunotherapy might be better than “therapeutic” active vaccination and also more efficient than passive antibody therapy, which can target probably only extracellular Mtb bacilli (112, 113). Unlike antibodies to B-cell epitopes [including those directed against overlapping T and B epitopes (114)], TcR-like ligands would be directed against epitopes, displayed in complex with MHC molecules on the surface of Mtb-infected cells.
Development of immunotherapeutic agents with TcR specificity has become feasible with the introduction of two technologies: (1) single chain antibody fragments (scFv) with TcR specificity can be selected from phage antibody libraries (115–118); (2) monomeric high affinity soluble human TcRs (mTcRs) have been expressed from cloned CD8 T cells and produced within the cytoplasm of trxB gor mutant E. coli strains (119). TcR-like mAbs against HLA class I presented epitopes of tumors (120) and virus-infected cells are being developed as novel immunotherapeutics with epitope-specific killing potentials, as well as diagnostic reagents (118). Moreover, genetic fusion of Pseudomonas exotoxin with TcR-like mAbs amplified the killing tumor cells (121, 122).

These advances, particularly in epitope-specific cancer immunotherapy, seem attractive for the development of TB immunotherapy. Production of mAb and mTcR ligands needs to target some of the empirically identified HLA class I immunodominant epitopes, which have been mapped for a number of Mtb antigens (26, 33, 34, 91, 123, 124). However, a similar approach to MHC class II-presented epitopes could be much more difficult, because their expression is impaired in infected macrophages (125) and because the procedures for producing the corresponding TcR-like ligands are yet underdeveloped. However, some concerns need to be addressed: immunodominance of the currently known MHC class I epitopes may have resulted from peptide presentation by dendritic cells or by cross-presentation, while a TcR-based immunotherapy would need to be targeted against epitopes expressed by infected macrophages. Therefore, it is a prerequisite to confirm the specificity and density of epitope expression on Mtb-infected macrophages. This needs to be ascertained by their capacity to stimulate CD8 T-cell clones or better by direct detection of the levels of epitope expression by antibody staining (126), or by tandem mass spectrometry (127). Notably, the latter technique showed that epitope abundance does not necessarily associate with the immunodominance hierarchy of epitopes.

Since apoptosis of macrophages is known to be the key mechanism for the killing of intracellular mycobacteria (128, 129), conjugation of TcR-specific ligands with apoptosis-inducing agents may amplify the therapeutic effect. Suitable candidate compounds for this purpose, with proven apoptosis-inducing capacity are Pseudomonas exotoxin A (130), granzyme B (131, 132), or BH3 peptide (133, 134).

Further synergistic benefit may come from recombinant IFNγ treatment, which enhances the surface expression of MHC-bound epitopes and has even alone been therapeutically beneficial in TB patients (135).

TREGITOpES
Tregitopes are epitopes, mostly in the Fc and constant Fab region of IgG, with highly conserved structure between mammalian species. They bind promiscuously to HLA class II molecules and stimulate and expand CD25 (+) FoxP3 (+) natural regulatory T cells (nTreg) (136). Tregitopes were shown to inhibit CD8 T-cell responses to co-administered antigens, with potentials to prevent or treat autoimmune disease, e.g., Type 1 diabetes or suppress allo-specific responses in mouse models. Co-administration of Tregitopes and auto-antigens reduced diabetes in NOD mice, while the in vitro response of T cells from diabetic patients to GAD65 epitopes was found suppressed by Tregitopes (137). Tregitopes might also prevent immune responses against hyper-variable Ig Ids, generated by somatic mutations.

The long-known therapeutic effects of intravenous human gamma globulin therapy (ivG) in autoimmune or allergic diseases, organ transplantation, and graft-versus-host disease have been attributed to the presence of Tregitopes in IgG (136, 138). The proposed mechanism as ivG-induced immunological tolerance has been supported by the increase of Treg cells and IL-10 production after ivG treatment. This concept is relevant to TB, considering the finding that intranasal or intraperitoneal inoculations of human gamma globulin inhibited the BCG viable counts in the lungs of intranasally infected mice (139, 140). Although the authors attributed this effect to the action of specific antibodies, an alternative possible explanation could involve the role of Tregitopes.

Increased Treg numbers in patients with active TB depress the IFNγ-secreting T-cell response to a protective antigen, such as the heparin binding hemagglutinin (141). Mycobacterium-activated human CD8 Treg cells co-express CD3γ, which is involved in the suppression of CD4 Th1 cell proliferation, lymphocyte activation, and express also LAG-3 and CCL4 (142). Impairing the function of Tregs in mice reduced Mb infection (143), but antibody inactivation of Tregs, which increased the immune response did not affect the bacterial load after infection (144) and did not influence protection by BCG vaccination (145). In view of these discrepancies about the possible Treg function in TB and the lack of knowledge about their specificity, the possible role of Tregitope recognition deserves further study.

CONCLUSION
Epitope specificity of immune responses of Mtb-infected hosts is significant for the immunopathogenesis of TB and its knowledge is mandatory for the development of new approaches toward TB control. HLA-permissive epitopes may have evolved in the tubercle bacilli due to the advantage from immune reactions, which lead to protracted transmission of the infection. Further research needs to expand knowledge on associations between epitope specificity with different effector and regulatory T-cell populations. It is proposed that combining of the biosignature of the T-cell phenotype with epitope specificity might lead to the discovery of protection and disease-associated biomarkers. There are important potentials toward the future development of epitope-defined diagnostics, prophylactic vaccines, and immunotherapies.

ACKNOWLEDGMENTS
I thank for collaboration all co-authors, quoted in the several joint publications.

REFERENCES
1. Ivanyi J. Pathogenic and protective interactions in mycobacterial infections. Clin Immunol (1986) 6:127–57.
2. Ivanyi J, Morris IA, Keen M. Studies with monoclonal antibodies to mycobacteria. In: Macario AJL, Macario EC, editors. Monoclonal Antibodies Against Bacteria. New York: Academic Press (1985). p. 59–90.
3. Ivanyi J, Sharp K, Jackett P, Bothamley G. Immunological study of the defined constituents of mycobacteria. Springer Semin Immunopathol (1988) 10:279–300. doi:10.1007/BF02053841

www.frontiersin.org March 2014 | Volume 5 | Article 107 | 7
Ivanyi Epitope functions and potentials

4. Young RA, Bloom BR, Grosskinsky CM, Ivanyi J, Thomas D, Davis RW. Dissection of Mycobacterium tuberculosis antigens using recombinant DNA. Proc Natl Acad Sci U S A (1985) 82:2568–72. doi:10.1073/pnas.82.8.2583

5. Lamb JR, Ivanyi J, Rees AD, Rothbard JB, Howland K, Young RA, et al. Mapping of T cell epitopes using recombinant antigens and synthetic peptides. EMBO J (1987) 6:1245–9.

6. McMurry JA, Kimball S, Lee HJ, Rivera D, Martin W, Weiner DB, et al. Epitope-driven TB vaccine development: a streamlined approach using immunoinformatics, ELLSpot assays, and HLA transgenic mice. Curr Mol Med (2007) 7:351–68. doi:10.2174/156652407780831584

7. Vordermeier M, Whelan AO, Hewigson RW. Recognition of mycobacterial epitope by T cells across mammalian species and use of a program that predicts human HLA-DR binding peptides to predict bovine epitopes. Infect Immun (2003) 71:1980–7. doi:10.1128/IAI.71.4.1980-1987.2003

8. Scarabelli G, Morra G, Colomba G. Predicting interaction sites from the energetics of isolated peptides: a new approach to epitope mapping. Biophys J (2010) 98:1966–75. doi:10.1016/j.bpj.2010.01.014

9. Berry MP, Blankley S, Graham CM, Bloom CJ, O’Garra A. Systems approaches to studying the immune response in tuberculosis. Curr Opin Immunol (2013) 25:579–87. doi:10.1016/j.coi.2013.08.003

10. Ernst JD, Lewinsohn DM, Behar S, Blythe M, Schlesinger LS, Kornfeld H, et al. Human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 peptide specific for the secretory mycobacterial antigen Ag85A. Clin Exp Immunol (2001) 123:226–32. doi:10.1111/j.1365-2249.2001.01450.x

11. Lindestam Arlehamn CS, Gerasimova A, Mele F, Henderson R, Swann J, Greenbaum JA, et al. Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigentic islands and largely contained in a CXC3B-CC3B+ Th1 subset. PLoS Pathog (2013) 9:e1003130. doi:10.1371/journal.ppat.1003130

12. Axelsson-Robertson R, Magalhaes I, Parida SK, Zumla A, Maeurer M. The characterization of HLA-DR- and TCR-binding residues of an immunodominant peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles. J Immunol (2004) 172:1966–77.

13. Brett SJ, Lamb JR, Cox JH, Rothbard JB, Mehlert A, Ivanyi J. Differential pattern of T cell recognition of the 65-kDa mycobacterial antigen following immunization with the whole protein or peptides. Eur J Immunol (1989) 19:1303–10. doi:10.1002/eji.1830190723

14. Vordermeier HM, Harris DP, Roman E, Lathigra R, Moreno C, Ivanyi J. Identification of overlapping epitope core sequences recognized in association with multiple major histocompatibility complex class II molecules. Infect Genet Evol (2015) 42:1023–39. doi:10.1016/j.meegid.2015.09.023

15. Harris DP, Vordermeier HM, Friscia G, Roman E, Surcel HM, Moreno C, et al. T cell repertoire in tuberculosis: selective anergy to an immunodominant epitope of the 38-kDa antigen in patients with active disease. Eur J Immunol (1992) 22:2631–7. doi:10.1002/eji.1830221024

16. Friscia G, Vordermeier HM, Pasvol G, Harris DP, Moreno C, Ivanyi J. Human T cells responses to peptide epitopes of the 16-kD antigen in tuberculosis. Clin Exp Immunol (1995) 105:53–7. doi:10.1111/j.1365-2249.1995.tb06635.x

17. Weichold FF, Mueller S, Kortok S, Hizler WE, Wulf MJ, Hone DM, et al. Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T cell response in patients with pulmonary tuberculosis. Genes Immun (2007) 8:334–43. doi:10.1038/sj.gene.6503492

18. Axelsson-Robertson R, Weichold F, Sizemore D, Wulf M, Shams H, et al. Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CTD T-cell responses. Immunology (2010) 129:496–505. doi:10.1111/j.1365-2567.2009.03201.x

19. Jurcevic S, Travers PJ, Hills A, Agrewala IN, Moreno C, Ivanyi J. Distinct conformations of a peptide bound to HLA-DR1 or DRB5*0101 suggested by molecular modelling. Int Immunol (1996) 8:1107–14. doi:10.1093/immunol/8.11.1107
41. Kiessling R, Gronberg A, Ivanjy J, Soderstrom K, Fern M, Kleinau S, et al. Role of hs6p60 during autoimmune and bacterial infection. Immunol Rev (1991) 121:91–111. doi:10.1111/j.1600-065X.1991.tb00824.x
42. Wick G, Kleinrasten R, Schett G, Amberger A, Xu Q. Role of heat shock protein 65/60 in the pathogenesis of artherosclerosis. Int Arch Allergy Immunol (1995) 107:130–1. doi:10.1159/000256592
43. Van Eden W, Wick G, Albani S, Cohen I. Stress, heat shock proteins, and autoimmunity: how immune responses to heat shock proteins are to be used for the control of inflammatory diseases. Ann NY Acad Sci (2007) 1113:217–37. doi:10.1196/annals.1391.020
44. Grundman C, Keutmann SB, Almanzar G, Wick G, McC G. Heat shock protein 60 and immune inflammatory responses in artherosclerosis. Arterioscler Thromb Vasc Biol (2011) 31:940–8. doi:10.1161/ATVBAHA.111.217877
45. Raine CS, Wu E, Ivanjy J, Katz D, Brosnan CF. Multiple sclerosis: a protective role of the immune system. Neurology (1987) 37:217–21.
46. Mackworth-Y oung CG, Cairns E, Sabbaga J, Massicotte H, Diamond B, Bell DA, et al. Antibodies to Mycobacterium tuberculosis. In: Bloom BR, editor. Understanding Tuberculosis: Analyzing the Origin of Mycobacterium tuberculosis Pathogenicity in infection? In: Cardona P-J, editor. Arthropods,taxonomy, behavior, and evolution of host-parasite interactions. J Exp Biol (2012) 1645–7. doi:10.1242/jeb.012466
47. Ivanyj J. Recall of antibody synthesis to the primary antigen following successive infections. Immunol Rev (2011) 130:354–9. doi:10.1111/j.0898-1109.2007.tb00249.x
48. Bothamley G, McC B, Britton W, Elsaghier A, Ivanjy J. Antibodies to ESAT-6. Infect Immun (2002) 70:2313–8. doi:10.1128/IAI.01246-09
49. Caccamo N, Dieli F. Are polyfunctional cells protective in tuberculosis infection? In: Cardona P-J, editor. Arthropods, taxonomy, behavior, and evolution of host-parasite interactions. J Exp Biol (2012) 1645–7. doi:10.1242/jeb.012466
50. Arlehamn CS, Sidney J, Henderson R, Greenbaum JA, James EA, Moutaftsi M, et al. Dissecting mechanisms of immunodominance to the common tuberculosis antigen ESAT-6. CFP10, Rv2654c(hspX), Rv2656c(TBP77), and Rv3836c(Essl). J Immunol (2012) 188:3020–31. doi:10.4049/jimmunol.0110535
51. Jackett PS, Bothamley GH, Batra HV , Mistry A, Y oung DB, Ivanjy J. Specificity of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins. Lab Invest (1996) 74:305–9. doi:10.1038/labinvest.370114a0
52. Updekar S, Heyn B, Erro S, Rougemont J, Cole ST. Comparative genomics of Esx from clinical isolates of Mycobacterium tuberculosis: evidence for gene conversion and epitope variation. Infect Immun (2011) 79:4042–9. doi:10.1128/IAI.05344-11
53. Jones GJ, Gordon SW, Hewinson RG, Vordermeier HM. Screening of predicted secreted antigens from Mycobacterium bovis reveals the immunodominance of the ESAT-6 protein family. Infect Immun (2010) 78:326–32. doi:10.1128/IAI.01246-09
54. Chegou NN, Heyckendorf J, Walz G, Lange C, Ruhwald M. Beyond the IFN-gamma horizon: biomarkers for immunodiagnosis of infection with M. tuberculosis. Eur J Resp J (2013). doi:10.1183/09031936.00129412
55. Dieli F, Friscia G, Di Sano C, Ivanjy J, Singh M, Spallek R, et al. Sequestration of T lymphocytes to body fluids in tuberculosis: reversal of anergy following chemotherapy. J Infect Dis (1998) 178:760–8. doi:10.1086/351336
56. Dieli F, Friscia G, Di Sano C, Ivanjy J, Singh M, Spallek R, et al. Sequestration of T lymphocytes to body fluids in tuberculosis: reversal of anergy following chemotherapy. J Infect Dis (1998) 178:760–8. doi:10.1086/351336
57. Dalsgaard C, Dieli F, Are polyfunctional cells protective in M. tuberculosis infection? In: Cardona P-J, editor. Understanding Tuberculosis: Analyzing the Origin of Mycobacterium tuberculosis Pathogenicity. Rieka: InTech (2012). p. 313–42.
58. Goletti D, Carrara S, Muyanja-Kizza H, Basek J, Mugerwa MA, Girardi E, et al. Response to M. tuberculosis selected RDI peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. BMC Infect Dis (2008) 8:11. doi:10.1186/1471-2334-8-11
59. Geldmacher C, Nguyenam N, Schuetz A, Petrovics C, Reiter K, Heeregraeven EI, et al. Preference of injection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med (2010) 207:2869–81. doi:10.1084/jem.20100090
60. Singh SP , Mehra NK, Dingley HB, Pande JN, Vaidya MC. Human leukocyte antigen (HLA) association of antibodies to Mycobacterium bovis infection in cattle using nanoparticle carriers for adsorbed antigens. J Control Release (2005) 102:551–61. doi:10.1016/j.jconrel.2004.10.034
61. Aabye MG, Latore I, Diaz J, Maldonado J, Mildh E, Eugen-Olsen J, et al. Dried plasma spots in the diagnosis of tuberculosis: IP-10 release assay on filter paper. Eur Resp J (2013) 42:495–503. doi:10.1183/09031936.00129412
62. Brahmajothi V , Pitchappan RM, Kakkanaiah VN, Sashidhar M, Rajaram K, et al. Preferential infection and depletion of EJ, et al. Polyfunctional cells protective in M. tuberculosis infection? In: Cardona P-J, editor. Understanding Tuberculosis: Analyzing the Origin of Mycobacterium tuberculosis Pathogenicity. Rieka: InTech (2012). p. 313–42.
Epitope functions and potentials

81. Rossi-Bergmann B, Muller I, Godinho EB, TH1 and TH2 T-cell subsets are differentially activated by macrophages and B cells in murine leishmaniasis. Infect Immun (1993) 61:2266–9.

82. Pitchappan RM, Agrewala JN, Dheenadhayalan V, Ivanyi J. Major histocompatibility complex restriction in tuberculosis susceptibility. J Bacteriol (1997) 22:47–57. doi:10.1128/jb.179.1.22-27.

83. Brett S, Orrell JM, Swanson Beck J, Ivanyi J. Influence of H-2 genes on growth of Mycobacterium tuberculosis in the lungs of chronically infected mice. Immunology (1992) 29:305–12.

84. Ivanyi J, Sharp K. Control by H-2 genes of murine antibody responses to protein antigens of Mycobacterium tuberculosis. Immunology (1986) 59:329–32.

85. Barcenas-Morales G, Merkenschlager M, Wahid F, Doffinger R, Ivanyi J. Reciprocal expression of the HLA-controlled immune response phenotype depends critically on antigen dose. Immunology (2000) 99:221–8. doi:10.1046/j.1365-2567.2000.00956.x.

86. Brett S, Ivanyi J. Genetic influences on the immune repertoire following tuberculous infection in mice. Immunology (1990) 71:113–9.

87. Orrell JM, Brett SJ, Ivanyi J, Coghill G, Grant A, Beck JS. Morphometric analysis of Mycobacterium tuberculosis infection in mice suggests a genetic influence on the generation of the granulomatous inflammatory response. J Pathol (1992) 166:77–82. doi:10.1002/path.1711660112.

88. Verbon A, Hartseelen RA, Moreno C, Kolk AH. Characterization of B cell epitopes on the 16k antigen of Mycobacterium tuberculosis. Clin Exp Immunol (1992) 89:395–401. doi:10.1111/j.1365-2249.1992.tb06969.x.

89. Vordermeier HM, Harris DP, Moreno C, Singh M, Ivanyi J. The nature of the immunogen determines the specificity of antibodies and T cells to selected peptides of the 38 kDa mycobacterial antigen. Int Immunol (1995) 7:559–66. doi:10.1093/immunol/7.5.559.

90. Harris DP, Hill M, Vordermeier HM, Jones M, Hewinson G, Thangaraj H, et al. Mutagenesis of an immunodominant T cell epitope can affect recognition of different T and B determinants within the same antigen. Mol Immunol (1997) 34:315–22. doi:10.1016/S0161-5890(97)00041-2.

91. Zhu X, Stauss HJ, Ivanyi J, Vordermeier HM. Specificity of CD8+ T cells from M. tuberculosis subunit-vaccinated and infected H-2b mice recognizing the 38 kDa antigen of Mycobacterium tuberculosis. Int Immunol (1997) 9:1669–76. doi:10.1093/immunol/9.11.1669.

92. Zhu X, Venkataprasad N, Thangaraj HS, Hill M, Singh M, Ivanyi J, et al. Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection. J Immunol (1997) 158:5921–6.

93. Bennennon T, Dietrich J, Rosenkrands I, Struyf A, Doherty TM, Andersen P. Alteration of epitope recognition pattern in AgSSB and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur J Immunol (2006) 36:3346–55. doi:10.1002/eji.200636128.

94. Tchilan E, Ahuja D, Hey A, Jiang S, Beverley P. Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy. Vaccine (2013) 31:4624–31. doi:10.1016/j.vaccine.2013.07.040.

95. Suzuki D, Nagata T, Eweda G, Matsumoto S, Matsumoto M, Tsujikura M, et al. Characterization of murine T-cell epitopes on mycobacterial DNA-binding protein 1 (MDP1) using DNA vaccination. Vaccine (2010) 28:2020–5. doi:10.1016/j.vaccine.2009.10.062.

96. Wang LX, Nagata T, Tsujikura K, Uchiyama M, Seto S, Koido Y. Identification of HLA-DR4-restricted T-cell epitope on MPT51 protein, a major secreted product derived from Mycobacterium tuberculosis using MPT51 overlapping peptides screening and DNA vaccination. Vaccine (2010) 28:2036–41. doi:10.1016/j.vaccine.2010.09.063.

97. Uto T, Tsujikura K, Uchiyama M, Seto S, Nagata T, Suda T, et al. A novel vaccine strategy to induce mycobacterial antigen-specific Th1 responses by utilizing the C-terminal domain of heat shock protein 70. FEBS Immunol Meas Microbiol (2011) 61:189–96. doi:10.1111/j.1574-695X.2010.00762.x.

98. Cox JH, Ivanyi J, Young DB, Lamb JR, Syed AD, Francis MJ. Orientation of epitope mutants. Mol Biotechnol (2010) 45:140–9. doi:10.1007/s12033-010-9250-0.

99. Michaela Y, Denkberg G, Sinik K, Lantzy L, Chih-Sheng C, Beauder C, et al. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies. J Immunol (2009) 182:8324–81. doi:10.4049/jimmunol.0801898.

100. Ivanyi J, Ensell S, Soueid-Baumgarten S, Oh SK, Bera T, Pastan I, et al. Targeting TARP, a novel breast and prostate tumor-associated antigen, with monoclonal antibodies without purification of antigen in the serodiagnosis of tuberculosis. J Immunol Methods (1985) 82:205–11. doi:10.1016/0022-1759(85)90032-1.

101. Wilkinson KA, Hudecz F, Vordermeier HM, Ivanyi J, Wilkinson RJ. Enhancement of the T cell response to a mycobacterial peptide by conjugation to synthetic branched polyepitide. Eur J Immunol (1999) 29:2788–96. doi:10.1002/sci.1521-4114(199909)29:09<2788::AID-IMMU2788>3.0.CO;2-4.

102. Goughaman U, Singh V, Zeng W, Jain S, Siddiqui KF, Chodisetti SB, et al. Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T-cell response. J Infect Dis (2011) 204:1328–38. doi:10.1093/infdis/jir548.

103. Brett SJ, Coates AR, Ivanyi J, Armitage J, Zerweck J, Hoft DF, et al. Modulation of peptide specific T cell responses by non-native flanking regions. J Immunol (2010) 184:140–9. doi:10.4049/jimmunol.0901088.
122. Klechevsky E, Gallegos M, Denkberg G, Palucka K, Banchereau J, Cohen C, et al. Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res (2008) 68:3660–7. doi:10.1158/0008-5472.CAN-08-0928

123. Caccamo N, Milano S, Di Sano C, Cigna D, Ivanyi J, Krenskey AM, et al. Identification of epitopes of Mycobacterium tuberculosis 16-kDa protein recognized by human leukocyte antigen-A*0201 CD8+ T lymphocytes. J Infect Dis (2002) 186:991–8. doi:10.1086/344174

124. Geluk A, van Meijgaarden KE, Franken KL, Drijfhout JW, D’Souza S, Necker M, et al. Macrophage apoptosis in mycobacterial infections. J Leukoc Biol (1999) 66:763–4.

125. Croft NP, Smith SA, Wong YC, Tan CT, Dudek NL I, Flesh E, et al. Kinetics of antigen expression and epitope presentation during virus infection. PLoS Pathog (2013) 9:e1003129. doi:10.1371/journal.ppat.1003129

126. Dadaglio G, Nelson CA, Deck MB, Petzold SJ, Unanue ER. Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Immunity (1997) 6:275–38. doi:10.1016/S1074-7613(00)80438-3

127. Fratacci C, Arvidsson CL, Carini C, Balcewicz-Sabcinska MK, Keane J, Kornfeld R, et al. Macrophage apoptosis in mycobacterial infections. J Leukoc Biol (1999) 66:763–4.

128. Dharap SS, Qiu B, Williams GC, Sinco P, Stein S, Minko T. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release (2003) 91:61–73. doi:10.1016/j.jconrel.2003.02.009

129. Moreau C, Carrrom PF, Hunt A, Mellah K, Green DR, Evan G, et al. Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins. J Biol Chem (2003) 278:19426–35. doi:10.1074/jbc.M209472200

130. Condor R, Raju B, Canova A, Zhao BY, Weiden M, Rom WN, et al. Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect Immun (2003) 71:2056–64. doi:10.1128/IAI.71.4.2056-2064.2003

131. Cowens LP, Najafian N, Mingozzi F, Elyman W, Mazer B, Moise L, et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol (2013) 33(Suppl 1):S54–9. doi:10.1007/s10875-012-9762-4

132. Noack J, Martinez-Bermejo J, Tollefsen J, Jourquin JM, Guiraud-Delannoy C, et al. Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res (2008) 68:3660–7. doi:10.1158/0008-5472.CAN-08-0928

133. Moreau C, Cartron PF, Hunt A, Mellah K, Green DR, Evan G, et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J Diabetes Res (2013) 2013:621693. doi:10.1155/2013/621693

Copyright © 2014 Ivanyi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which do not comply with these terms.